A carregar...
Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity
BACKGROUND: Spinal muscular atrophy (SMA) is a genetic disease characterized by degeneration of the spinal cord, resulting in progressive muscle atrophy. Recently, nusinersen has been approved for treating SMA, which should be administered intrathecally. CASE PRESENTATION: Patient 1 was a 36-year-ol...
Na minha lista:
| Publicado no: | JA Clin Rep |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7171013/ https://ncbi.nlm.nih.gov/pubmed/32314319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40981-020-00334-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|